Cryptolepine Targets TOP2A and Inhibits Tumor Cell Proliferation in Breast Cancer Cells - An In vitro and In silico Study
DNA Topoisomerase II Alpha (TOP2A), a protein-coding gene, is central to the replication process and has been found deregulated in several malignancies, including breast cancer. Several therapeutic regimens have been developed and approved for targeting TOP2A and have prolonged the survival of cance...
Saved in:
| Published in: | Anti-cancer agents in medicinal chemistry Vol. 22; no. 17; p. 3025 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Netherlands
01.01.2022
|
| Subjects: | |
| ISSN: | 1875-5992, 1875-5992 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | DNA Topoisomerase II Alpha (TOP2A), a protein-coding gene, is central to the replication process and has been found deregulated in several malignancies, including breast cancer. Several therapeutic regimens have been developed and approved for targeting TOP2A and have prolonged the survival of cancer patients. However, due to the inherent nature of the tumor cell to evolve, the earlier positive response turns into a refractory chemoresistance in breast cancer patients.
The study's main objective was to analyze the expression pattern and prognostic significance of TOP2A in breast cancer patients and screen new therapeutic molecules targeting TOP2A.
We utilized an integrated bioinformatic approach to analyze the expression pattern, genetic alteration, immune association, and prognostic significance of TOP2A in breast cancer (BC) and screened natural compounds targeting TOP2A, and performed an in silico and an in vitro analysis.
Our study showed that TOP2A is highly overexpressed in breast cancer tissues and overexpression of TOP2A correlates with worse overall survival (OS) and relapse-free survival (RFS). Moreover, TOP2A showed a high association with tumor stroma, particularly with myeloid-derived suppressor cells. Also, in silico and in vitro analysis revealed cryptolepine as a promising natural compound targeting TOP2A.
Cumulatively, this study signifies that TOP2A promotes breast cancer progression, and targeting TOP2A in combination with other therapeutic agents will significantly enhance the response of BC patients to therapy and reduce the development of chemoresistance. |
|---|---|
| AbstractList | DNA Topoisomerase II Alpha (TOP2A), a protein-coding gene, is central to the replication process and has been found deregulated in several malignancies, including breast cancer. Several therapeutic regimens have been developed and approved for targeting TOP2A and have prolonged the survival of cancer patients. However, due to the inherent nature of the tumor cell to evolve, the earlier positive response turns into a refractory chemoresistance in breast cancer patients.
The study's main objective was to analyze the expression pattern and prognostic significance of TOP2A in breast cancer patients and screen new therapeutic molecules targeting TOP2A.
We utilized an integrated bioinformatic approach to analyze the expression pattern, genetic alteration, immune association, and prognostic significance of TOP2A in breast cancer (BC) and screened natural compounds targeting TOP2A, and performed an in silico and an in vitro analysis.
Our study showed that TOP2A is highly overexpressed in breast cancer tissues and overexpression of TOP2A correlates with worse overall survival (OS) and relapse-free survival (RFS). Moreover, TOP2A showed a high association with tumor stroma, particularly with myeloid-derived suppressor cells. Also, in silico and in vitro analysis revealed cryptolepine as a promising natural compound targeting TOP2A.
Cumulatively, this study signifies that TOP2A promotes breast cancer progression, and targeting TOP2A in combination with other therapeutic agents will significantly enhance the response of BC patients to therapy and reduce the development of chemoresistance. DNA Topoisomerase II Alpha (TOP2A), a protein-coding gene, is central to the replication process and has been found deregulated in several malignancies, including breast cancer. Several therapeutic regimens have been developed and approved for targeting TOP2A and have prolonged the survival of cancer patients. However, due to the inherent nature of the tumor cell to evolve, the earlier positive response turns into a refractory chemoresistance in breast cancer patients.BACKGROUNDDNA Topoisomerase II Alpha (TOP2A), a protein-coding gene, is central to the replication process and has been found deregulated in several malignancies, including breast cancer. Several therapeutic regimens have been developed and approved for targeting TOP2A and have prolonged the survival of cancer patients. However, due to the inherent nature of the tumor cell to evolve, the earlier positive response turns into a refractory chemoresistance in breast cancer patients.The study's main objective was to analyze the expression pattern and prognostic significance of TOP2A in breast cancer patients and screen new therapeutic molecules targeting TOP2A.OBJECTIVEThe study's main objective was to analyze the expression pattern and prognostic significance of TOP2A in breast cancer patients and screen new therapeutic molecules targeting TOP2A.We utilized an integrated bioinformatic approach to analyze the expression pattern, genetic alteration, immune association, and prognostic significance of TOP2A in breast cancer (BC) and screened natural compounds targeting TOP2A, and performed an in silico and an in vitro analysis.METHODSWe utilized an integrated bioinformatic approach to analyze the expression pattern, genetic alteration, immune association, and prognostic significance of TOP2A in breast cancer (BC) and screened natural compounds targeting TOP2A, and performed an in silico and an in vitro analysis.Our study showed that TOP2A is highly overexpressed in breast cancer tissues and overexpression of TOP2A correlates with worse overall survival (OS) and relapse-free survival (RFS). Moreover, TOP2A showed a high association with tumor stroma, particularly with myeloid-derived suppressor cells. Also, in silico and in vitro analysis revealed cryptolepine as a promising natural compound targeting TOP2A.RESULTSOur study showed that TOP2A is highly overexpressed in breast cancer tissues and overexpression of TOP2A correlates with worse overall survival (OS) and relapse-free survival (RFS). Moreover, TOP2A showed a high association with tumor stroma, particularly with myeloid-derived suppressor cells. Also, in silico and in vitro analysis revealed cryptolepine as a promising natural compound targeting TOP2A.Cumulatively, this study signifies that TOP2A promotes breast cancer progression, and targeting TOP2A in combination with other therapeutic agents will significantly enhance the response of BC patients to therapy and reduce the development of chemoresistance.CONCLUSIONCumulatively, this study signifies that TOP2A promotes breast cancer progression, and targeting TOP2A in combination with other therapeutic agents will significantly enhance the response of BC patients to therapy and reduce the development of chemoresistance. |
| Author | Asdaq, Syed Mohammed Basheeruddin Mir, Manzoor Ahmad Shafi, Shazia Farhana, Pzd Mehraj, Umar Qayoom, Hina |
| Author_xml | – sequence: 1 givenname: Umar surname: Mehraj fullname: Mehraj, Umar organization: Department of Bioresources, School of Biological Sciences, University of Kashmir, Srinagar 190006, J&K India – sequence: 2 givenname: Hina surname: Qayoom fullname: Qayoom, Hina organization: Department of Bioresources, School of Biological Sciences, University of Kashmir, Srinagar 190006, J&K India – sequence: 3 givenname: Shazia surname: Shafi fullname: Shafi, Shazia organization: Department of Bioresources, School of Biological Sciences, University of Kashmir, Srinagar 190006, J&K India – sequence: 4 givenname: Pzd surname: Farhana fullname: Farhana, Pzd organization: Department of Bioresources, School of Biological Sciences, University of Kashmir, Srinagar 190006, J&K India – sequence: 5 givenname: Syed Mohammed Basheeruddin surname: Asdaq fullname: Asdaq, Syed Mohammed Basheeruddin organization: Department of Pharmacy Practice, College of Pharmacy, Almaarefa University, Riyadh 13713, KSA – sequence: 6 givenname: Manzoor Ahmad surname: Mir fullname: Mir, Manzoor Ahmad organization: Department of Bioresources, School of Biological Sciences, University of Kashmir, Srinagar 190006, J&K India |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35440335$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkNtKxDAQhoOsuAd9BYl33lSbY9vLtXhYWNgF1-uSNlONtElNWqFvb2VX8Gbmn5lvfoZZopl1FhC6IfEdJQm_J2lCBI0lpVJOIeYkI0wInpyhxTQTkcgyOvun52gZwmcccxFLcoHmTHAeMyYWaMz92PWugc5YwAfl36EP-LDb0zVWVuON_TCl-W0NrfM4h6bBe-8aU4NXvXEWG4sfPKjQ41zZCo5MwBFe22kbf5veu5MVDqYxlcOv_aDHS3ReqybA1Smv0NvT4yF_iba7502-3kYlT1gfJUJQJqqy5pJApmqu1KSpjjVjALLWNYFU05QpQmqtxVSBznhWplVZ8UzSFbo9-nbefQ0Q-qI1oZpuVBbcEAoqBU2lZJRM6PUJHcoWdNF50yo_Fn_voj_Ea3Bb |
| CitedBy_id | crossref_primary_10_1007_s12032_023_02067_w crossref_primary_10_1007_s12032_022_01748_2 crossref_primary_10_1007_s12672_025_03158_y crossref_primary_10_1038_s41598_025_16785_w crossref_primary_10_3389_fmolb_2025_1566293 crossref_primary_10_1016_j_cancergen_2024_10_005 crossref_primary_10_1038_s42003_024_07286_z crossref_primary_10_3389_fphar_2023_1333447 crossref_primary_10_1007_s12032_022_01811_y crossref_primary_10_1016_j_compbiolchem_2024_108164 crossref_primary_10_2174_0113816128304923240704113319 crossref_primary_10_1007_s12026_023_09376_2 crossref_primary_10_1016_j_sjbs_2023_103705 crossref_primary_10_1016_j_ijbiomac_2025_140627 crossref_primary_10_3389_fonc_2025_1591875 crossref_primary_10_1016_j_sjbs_2024_103935 crossref_primary_10_1080_07391102_2023_2252092 crossref_primary_10_1007_s12032_022_01861_2 crossref_primary_10_1007_s12032_022_01852_3 crossref_primary_10_3389_fphar_2022_958443 |
| ContentType | Journal Article |
| Copyright | Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. |
| Copyright_xml | – notice: Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.2174/1871520622666220419135547 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1875-5992 |
| ExternalDocumentID | 35440335 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .5. 0R~ 23M 36B 4.4 53G 5GY AAEGP AAVXF ABEEF ABJNI ABMOS ABVDF ACGFS ACITR ACZAY AENEX AFUQM AGJNZ ALMA_UNASSIGNED_HOLDINGS ANTIV C1A CGR CS3 CUY CVF EBS ECM EIF EJD F5P GH2 HZ~ IPNFZ KCGFV NPM O9- P2P RIG 7X8 AFHZU AGQPQ |
| ID | FETCH-LOGICAL-b473t-755235cbf461e9af4aabf42d0d33ee6fdf1e8d283a11fdd51e8ed949b8cbc4962 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 20 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000855254800009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1875-5992 |
| IngestDate | Fri Jul 11 11:54:10 EDT 2025 Thu Apr 03 07:03:40 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 17 |
| Keywords | TOP2A gene ontology Breast cancer prognosis cryptolepine bioinformatics |
| Language | English |
| License | Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b473t-755235cbf461e9af4aabf42d0d33ee6fdf1e8d283a11fdd51e8ed949b8cbc4962 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 35440335 |
| PQID | 2652866321 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2652866321 pubmed_primary_35440335 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-01-01 |
| PublicationDateYYYYMMDD | 2022-01-01 |
| PublicationDate_xml | – month: 01 year: 2022 text: 2022-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Anti-cancer agents in medicinal chemistry |
| PublicationTitleAlternate | Anticancer Agents Med Chem |
| PublicationYear | 2022 |
| SSID | ssj0045061 |
| Score | 2.4272258 |
| Snippet | DNA Topoisomerase II Alpha (TOP2A), a protein-coding gene, is central to the replication process and has been found deregulated in several malignancies,... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 3025 |
| SubjectTerms | Antigens, Neoplasm - genetics Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology Cell Proliferation DNA Topoisomerases, Type II - genetics DNA Topoisomerases, Type II - metabolism DNA-Binding Proteins - genetics Female Humans Indole Alkaloids - pharmacology Neoplasm Recurrence, Local Quinolines - pharmacology Topoisomerase II Inhibitors - pharmacology |
| Title | Cryptolepine Targets TOP2A and Inhibits Tumor Cell Proliferation in Breast Cancer Cells - An In vitro and In silico Study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35440335 https://www.proquest.com/docview/2652866321 |
| Volume | 22 |
| WOSCitedRecordID | wos000855254800009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEBZNtpRc0qaPZPsIEwg5RcR62atT2S4NzSFbH7awt0W2JGrY2tu1E_C_z8h2sqdCIRdhC8sI-fPMN5rRDCHnnqmc5QjezLqYykwbmkXMUuOR23PPgq-pKzaRzOeT5VKnw4ZbPYRVPsrETlDbKg975Fc8VnyC6pGzr5u_NFSNCt7VoYTGHhkJpDIB1cnyyYsgVdTnS0VOTpXW_BU5C6HPSMKvsA81VxQj-4ixiSTaLUH1Jv9mmp3GuX793Lm-IYcD14RpD44j8sKVb8lF2ierbi9hsTt7VV_CBaS7NNbtO9LOtu2mqdZug0QUFl3EeA2Lnymfgikt3JS_i6wIXXd_qi3M3HoNaagB5F2PKihK-BZi3huYBWz1z9RAYVriaLgvmm01vArqYo2YhBDW2L4nv66_L2Y_6FCogWYyEQ1NFJqzKs-8jJnTxktj8JrbyArhXOytZ25ikcgYxry1Cu-c1VJnkzzLpY75B7JfVqU7IYCWunUCxY5IPBpjRjsfScN8HnFnkH2Mydnjkq_wRwjeDVO66q5e7RZ9TI7777ba9Bk7VkJJGQmhPv7H6E_kgIcjDt02y2cy8igG3BfyMr9vinp72iEM23l6-wATYdpQ |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cryptolepine+Targets+TOP2A+and+Inhibits+Tumor+Cell+Proliferation+in+Breast+Cancer+Cells+-+An+In+vitro+and+In+silico+Study&rft.jtitle=Anti-cancer+agents+in+medicinal+chemistry&rft.au=Mehraj%2C+Umar&rft.au=Qayoom%2C+Hina&rft.au=Shafi%2C+Shazia&rft.au=Farhana%2C+Pzd&rft.date=2022-01-01&rft.eissn=1875-5992&rft.volume=22&rft.issue=17&rft.spage=3025&rft_id=info:doi/10.2174%2F1871520622666220419135547&rft_id=info%3Apmid%2F35440335&rft_id=info%3Apmid%2F35440335&rft.externalDocID=35440335 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1875-5992&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1875-5992&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1875-5992&client=summon |